The DOI matches its Crossref record; 198 of the 205 references it cites were found in a registry or an index.
The role of kinin receptors in cancer and therapeutic opportunities
Open accessAbstract
Kinins are generated within inflammatory tissue microenvironments, where they exert diverse functions, including cell proliferation, leukocyte activation, cell migration, endothelial cell activation and nociception. These pleiotropic functions depend on signaling through two cross talking receptors, the constitutively expressed kinin receptor 2 (B2R) and the inducible kinin receptor 1 (B1R). We have reviewed evidence, which supports the concept that kinin receptors, especially kinin receptor 1, are promising targets for cancer therapy, since (1) many tumor cells express aberrantly high levels of these receptors; (2) some cancers produce kinins and use them as autocrine factors to stimulate their growth; (3) activation of kinin receptors leads to activation of macrophages, dendritic cells and other cells from the tumor microenvironment; (4) kinins have pro-angiogenic properties; (5) kinin receptors have been implicated in cancer migration, invasion and metastasis; and (6) selective antagonists for either B1R or B2R have shown anti-proliferative, anti-inflammatory, anti-angiogenic and anti-migratory properties. The multiple cross talks between kinin receptors and renin-angiotensin system (RAS) as well as its implications for targeting KKS or RAS for the treatment of malignancies are also discussed. It is expected that B1R antagonists would interfere less with housekeeping functions and therefore would be attractive compounds to treat selected types of cancer. Reliable clinical studies are needed to establish the translatability of these data to human settings and the usefulness of kinin receptor antagonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Captopril usage has improved the accumulation of paclitaxel-loaded nanoparticles in U87 glioma xenograft tumors [40,41,42].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [40]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Vascular endothelial cells synthesize nitric oxide from L-arginine
Palmer, R. M. J., Ashton, D., & Moncada, S. (1988) · Nature · doi:10.1038/333664a0 · Cited by 4,786
Pharmacology of bradykinin and related kinins.
Regoli, D. C., & Barabé, J. (1980) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06836-x · Cited by 1,900
Papapetropoulos, A., García‐Cardeña, G., Madri, J. A., & Sessa, W. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119868 · Cited by 1,195
THE PREPARATION AND FUNCTION OF THE HYPERTENSIN-CONVERTING ENZYME
Skeggs, L. T., Kahn, J. R., & Shumway, N. P. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.103.3.295 · Cited by 1,035
Leeb-Lundberg, L. M. F., Marceau, F., Müller‐Esterl, W., Pettibone, D. J., & Zuraw, B. L. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.2 · Cited by 956
Silva, M. R. E., Beraldo, W. T., & Rosenfeld, G. (1949) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1949.156.2.261 · Cited by 828
Differential exoprotease activities confer tumor-specific serum peptidome patterns
Villanueva, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26022 · Cited by 738
The renin-angiotensin-aldosterone system
Vecsei, P., Hackenthal, E., & Ganten, D. (1978) · Journal of Molecular Medicine · doi:10.1007/bf01477448 · Cited by 604
Flagged first, then by citations
7 of the 205 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Chee, 2008, Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer, Biol. Chem., 389, 1225, 10.1515/BC.2008.139 · DOI
Cited by
Sorted by citations
Items 101–134 of 134
Kinin B1 receptor and TLR4 interaction in inflammatory response
Batista, C., Cruz, J. V. R., Stipursky, J., Mendes, F. A., & Pesquero, J. B. (2024) · Inflammation Research · doi:10.1007/s00011-024-01909-1 · Cited by 2
Liu, Y., Gao, P., Wang, Z., Li, R., Meng, K., Le, W., & Tang, Y. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00485-6 · Cited by 2
Kilstein, Y., Nowak, W., Errasti, A. E., Feas, A. A. B., Armesto, A. R., Pelorosso, F. G., & Rothlin, R. P. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.230169 · Cited by 2
Kinin Receptors in Skin Wound Healing
Soley, B. D. S., Horinouchi, C. D. D. S., Pawloski, P. L., Otuki, M. F., & Cabrini, D. A. (2018) · Recent clinical techniques, results, and research in wounds · doi:10.1007/15695_2018_136 · Cited by 2
Gowda, P., & Sen, E. (2020) · doi:10.21203/rs.3.rs-23656/v1 · Cited by 2
Exploring metabolic pathways in gastrointestinal cancer: new evidence of causality
Wang, Z., Wang, C., & Gao, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-03618-5 · Cited by 1
Samuel, M. (2017) · Cancer and Oncology Research · doi:10.13189/cor.2017.050202
Antihypertensive Role of Kidney: Focus on Tissue Kallikreins
Mandal, A., Chakraborti, T., & Chakraborti, S. (2017) · Springer eBooks · doi:10.1007/978-981-10-6141-7_26 · Cited by 1
Scharfstein, J. (2016) · Compendium of Inflammatory Diseases · doi:10.1007/978-3-7643-8550-7_127 · Cited by 1
Plasma Kinins- A Pharmacological Perspective
Jefry Winner, G., & Anusha, N. (2022) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2022/v34i577254 · Cited by 1
Bradshaw, R. A., & Lundblad, R. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.10090-2 · Cited by 1
Bioinformatic Studies on Buffalo Prolactin Derived Anti-Angiogenic Peptide
Kumar, P., & Singh, P. (2016) · Journal of Science Humanities and Arts - JOSHA · doi:10.17160/josha.3.3.193
PET/CT imaging of the human bradykinin 1 receptor using radiolabeled peptides for cancer detection
Amouroux, G. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0308742
Leczenie bólu u chorych na raka płuca
Nurwidya, F., Syahruddin, E., & Yunus, F. (2017) · Advances in respiratory medicine · doi:10.5603/arm.50370
Impact of Renin-Angiotensin System Inhibitors On The Survival of Patients With Rectal CancerPreprint
Zeman, M., Skałba, W., Wilk, A., Cortez, A. J., Maciejewski, A., & Czarniecka, A. (2021) · Research Square · doi:10.21203/rs.3.rs-984417/v1
Scharfstein, J. (2015) · Encyclopedia of Inflammatory Diseases · doi:10.1007/978-3-0348-0620-6_127-1
Kallikrein and Kallikrein-Related Peptidases
Bradshaw, R. A., & Lundblad, R. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00051-1
Scharfstein, J. (2016) · Encyclopedia of Inflammatory Diseases · doi:10.1007/978-3-0348-0620-6_127-2
Lee, J., Kumar, P., Suganya, N., Park, S. H., Majumder, S., Sundaresan, L., Muralidhar, K., Choi, J., Lee, H. J., & Chatterjee, S. (2024) · FEBS Open Bio · doi:10.1002/2211-5463.13895
Bradykinin-related peptides and their receptors from nonmammalian vertebrates
Qin, H., & Kwok, H. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28907-1.00003-7
Neculqueo, G. W., & Campos, M. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28907-1.00006-2
Zeman, M., Skałba, W., Wilk, A., Cortez, A. J., Maciejewski, A., & Czarniecka, A. (2022) · Figshare · doi:10.6084/m9.figshare.20372734
Zeman, M., Skałba, W., Wilk, A., Cortez, A. J., Maciejewski, A., & Czarniecka, A. (2022) · Figshare · doi:10.6084/m9.figshare.20372737
Anitua, E., Cerqueira, A., Romero‐Gavilán, F., García‐Arnáez, I., Martínez‐Ramos, C., Ozturan, S., Azkargorta, M., Elortza, F., Gurruchaga, M., Goñi, I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457210
Anitua, E., Cerqueira, A., Romero‐Gavilán, F., García‐Arnáez, I., Martínez‐Ramos, C., Ozturan, S., Azkargorta, M., Elortza, F., Gurruchaga, M., Goñi, I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457207
Anitua, E., Cerqueira, A., Romero‐Gavilán, F., García‐Arnáez, I., Martínez‐Ramos, C., Ozturan, S., Azkargorta, M., Elortza, F., Gurruchaga, M., Goñi, I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457201
Anitua, E., Cerqueira, A., Romero‐Gavilán, F., García‐Arnáez, I., Martinez-Ramos, C., Ozturan, S., Azkargorta, M., Elortza, F., Gurruchaga, M., Goñi, I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457213
Zeman, M., Skałba, W., Wilk, A., Cortez, A. J., Maciejewski, A., & Czarniecka, A. (2022) · Figshare · doi:10.6084/m9.figshare.20372728
Anitua, E., Cerqueira, A., Romero‐Gavilán, F., García‐Arnáez, I., Martínez‐Ramos, C., Ozturan, S., Azkargorta, M., Elortza, F., Gurruchaga, M., Goñi, I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457198
Anitua, E., Cerqueira, A., Romero‐Gavilán, F., García‐Arnáez, I., Martínez‐Ramos, C., Ozturan, S., Azkargorta, M., Elortza, F., Gurruchaga, M., Goñi, I., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14457204
Shimon, S. M. M., Meneghetti, M. C. Z., Bromberg, N., Cavalheiro, R. P., Palomino, C. M. V., Carvalho, R. S. M., Ferreira, A. C., Nader, H. B., Pinhal, M. A. D. S., Nascimento, F. D., et al. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109810
Molecular mechanisms for subtype selectivity of kinin receptors’ antagonists
Meng, X., Raskovalov, A., Nguyen, M. V. T., Mei, S., Kim, D., Salve, J., Katritch, V., Cherezov, V., & Zhang, H. (2026) · Nature Communications · doi:10.1038/s41467-026-73412-6
Pei, W., Mu, J., Ding, C., Ni, S., Wang, Y., Xia, Y., Wang, W., Xu, S., Feng, Y., Li, L., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117988
Metadata
- Authors
- da Costa, P. L. N., Sirois, P., Tannock, I. F., & Chammas, R.
- Affiliations
- University of Toronto (CA)
- Universidade de São Paulo (BR)
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 345
- Issue
- 1
- Pages
- 27-38
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2090131666
- Cited by
- 133
- References
- 205
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 16 · 2021: 17 · 2020: 8 · 2019: 6 · 2018: 17 · 2017: 6 · 2016: 21 · 2015: 6 · 2014: 4
- FWCI
- 1.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Letters (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Topics
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pineapple and bromelain studies
- Keywords
- kinin receptors, B1 receptor, bradykinin B2 receptor, kinin receptor antagonists, cancer therapy, tumor microenvironment, angiogenesis, metastasis, renin-angiotensin system, autocrine signaling, macrophage activation, dendritic cells
- MeSH terms
- Animals, Humans, Neoplasms, Signal Transduction, Receptor, Bradykinin B2, Receptor, Bradykinin B1, Molecular Targeted Therapy, Bradykinin B2 Receptor Antagonists, Bradykinin B1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review